Advertisement

Topics

Latest "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" News Stories

04:56 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" found in our extensive news archives from over 250 global news sources.

More Information about A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects for you to read. Along with our medical data and news we also list A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects Companies for you to search.

Showing "Phase Safety Immunogenicity Study Seronegative Subjects" News Articles 1–25 of 29,000+

Friday 22nd February 2019

Poison control calls for #kratom increase from one a month to two a day, study shows http://bit.ly/2GX9c5k  #HerbalMedicines #pharmapic.twitter.com/b3DrPwd2w3

Poison control calls for #kratom increase from one a month to two a day, study shows http://bit.ly/2GX9c5k  #HerbalMedicines #pharma pic.twitter.com/b3DrPwd2w3


Propeller Health study reveals majority people use inhalers incorrectly

Propeller Health s, along with the University of Colorado School of Medicine and Children’s Hospital Colorado, has carried out the study that showed majority of asthma patients using The post Propeller Health study reveals majority people use inhalers incorrectly appeared first on Compelo Medical Devices.

Happy Life and PPD to Offer China Clinical Trial/Post-Marketing Services

Happy Life Tech of Beijing, an AI-based clinical/post-marketing CRO, teamed up with Pharmaceutical Product Development, a global clinical-stage CRO, to provide drug developers in China with clinical trial management and post-launch testing. The two companies expect their alliance will help to bring foreign drugs to China and, conversely, bring China drug products to global markets. The collaborati...


Xbrane Biopharma releases Year-end report for 2018

Press release2019-02-22  Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end report for 2018 is now available on the Company's website, www.xbrane.com. The fourth quarter 2018 in summary Revenue amounted to SEK 4,896 thousand (9,535). Gross margin amounted to 25% (24). Other operating income amounted to SEK 1,

FDA hits leukemia study with partial clinical hold

The FDA has placed a partial clinical hold on Xencor's Phase I study of XmAb14045 on safety concerns.

MHRA issues drug safety warning for Neo-mercazole in pregnancy

The MHRA has issued a drug safety warning for Neo-mercazole in pregnancy, urging women of childbearing potential to use effective contraception during treatment

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv The post Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure appeared first on Pharmaceutical Business review.

Thursday 21st February 2019

IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial

Today's Daily Dose brings you news about Exact Sciences' better-than-expected Q4 financial results; Merck's acquisition of Immune Design; Nevro's lackluster revenue outlook; Opiant Pharma' s disappointing Bulimia Nervosa study results; and near-term catalyst of Zosano Pharma.

Mallinckrodt gibt Ergebnisse der Zwischenanalyse aus klinischer Phase-3-Studie für Therakos® Plattform zur Behandlung von pädiatrischen Patienten mit steroidrefraktärer akuter Graft-versus-Host-Krankheit bekannt

-- Allgemeine Ansprechrate übertrifft das für die Halbzeit der Studie spezifizierte Ziel (n=25); Unternehmen entscheidet sich dafür, die Rekrutierung weiterer Patienten wie vom Protokoll vorgesehen...

Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019

Aradigm Corporation (Pink Market: ARDM) (“Aradigm” or the “Company”). At the Type B meeting, Aradigm presented the results of the Third Party Evaluation (TPE) completed in December 2019 that addressed the clinical issue raised by the FDA in the complete response letter (CRL) received in January 2018. As previously announced, the TPE results confi...

[Articles] Anal incontinence after caesarean and vaginal delivery in Sweden: a national population-based study

The risk of developing anal incontinence increases after pregnancy and delivery. Women with known risk factors for anal incontinence should perhaps be offered a more qualified post-partum examination to enable early intervention in case of injury. Further knowledge for optimal management are needed.

'Placenta-on-a-chip' models caffeine transport from mother to foetus

Developing inside a woman’s uterus during pregnancy, the placenta (through the umbilical cord) provides oxygen and nutrients to the foetus and removes waste from the foetal bloodstream. But animal models of the placenta don’t translate well to human health, and because of its temporary nature there haven’t been a lot of human studies — and those that have been done have shown inconsistent ...

Besides the U.S., drug overdose mortality is also common in other high-income countries

Is the current American drug overdose epidemic an isolated phenomenon? Have other high-income countries experienced similar increases in drug overdose mortality, or are they likely to going forward? A new study published in Population and Development Review addresses these questions.

Study doesn’t find enough evidence related to effects of noncaloric sweeteners on gut microbiota

The study, carried out by the UGR professor of Biochemistry and Molecular Biology Ángel Gil and his research team, has been published in the scientific journal 'Advances in Nutrition'

Phase 1 data reinforce safety profile of new drug for treating Duchenne muscular dystrophy

Patients with Duchenne muscular dystrophy (DMD) have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects.

Venezuela crisis could spark surge in infectious diseases - study

A humanitarian crisis in Venezuela is accelerating the re-emergence of malaria, Chagas disease, dengue, Zika and other dangerous infectious diseases and threatens to jeopardize 20 years of public health gains, experts warned on Thursday.

Vitamin D supplementation less effective in the presence of obesity, shows study

A new Journal of Bone and Mineral Research study confirms that vitamin D supplementation is less effective in the presence of obesity, and it uncovers a biological mechanism to explain this observation.

Why Flu Vaccines Don’t Work as Well in the Elderly

The adage that “the older you are, the wiser you get” doesn’t always apply to our immune systems. Despite being exposed to a lifetime’s worth of illnesses, immune systems in the elderly are worse at fighting stealthy, shape-shifting viruses like the flu. Why aging decreases our immune system’s abilities has been a mystery to researchers. But a new study published in Cell Host & Micr...

Did http://Stamps.com  miss on a phase 3 NASH trial?pic.twitter.com/SZcrY7K98W

Did http://Stamps.com  miss on a phase 3 NASH trial? pic.twitter.com/SZcrY7K98W

Firmly on our way to becoming a fully integrated biopharma company

Revenues doubled in 2018 Key 2018 clinical results: FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability TORTUGA and EQUATOR Phase 2 trials with filgotinib in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) met primary endpoints with consistent tolerability Initiated ISABELA, a gl...

Study calls for better collaboration between cardiologists, oncologists

HCA Healthcare Appoints Meg Crofton as New Independent Director

HCA Healthcare (NYSE: HCA) today announced that its board of directors has appointed Meg Crofton as an independent director, effective March 1, 2019. With her addition, HCA Healthcare’s board of directors increases from 12 to 13 members. Ms. Crofton will also serve as a member of HCA Healthcare’s compensation committee and patient safety and quality of ...

$OPNT #FAIL Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa https://globenewswire.com/news-release/2019/02/21/1739815/0/en/Opiant-Pharmaceuticals-Announces-Top-line-Results-from-Phase-2-Clinical-Trial-of-OPNT001-fo

$OPNT #FAIL Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa https://globenewswire.com/news-release/2019/02/21/1739815/0/en/Opiant-Pharmaceuticals-Announces-Top-line-Results-from-Phase-2-Clinical-Trial-of-OPNT001-for-Treatment-of-Bulimia-Nervosa.html …

Women don’t want to wait for their mammogram results, study finds

$CALA Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis. Study completion anticipated in 2019 https://finance.yahoo.com/news/calithera-biosciences-initiates-phase-1-210500885.html …

$CALA Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis. Study completion anticipated in 2019 https://finance.yahoo.com/news/calithera-biosciences-initiates-phase-1-210500885.html …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks